Your session is about to expire
← Back to Search
Ixabepilone for Breast Cancer
Study Summary
This trial compares ixabepilone to standard of care for treating patients with HER2/Neu negative breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 3 trial • 799 Patients • NCT00785291Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your platelet count is at least 100,000 per cubic millimeter.I have not had any cancer except for skin or cervical cancer in the last 5 years.I do not have any severe health issues that could affect my participation in the study.My cancer has spread to distant parts of my body.I have cancer in both breasts.I am mostly able to care for myself and carry out normal activities.My kidney function, measured by creatinine, is normal.I am using effective birth control and will continue for 6 months after my treatment ends.I am using or willing to use effective birth control during the study.My cancer tests positive for HER2 protein or gene changes.I stopped my treatment because my condition got worse.Your liver enzymes (ALT and AST) can be slightly higher than normal, but not more than 1.5 times the upper limit of what's considered normal at the hospital.Your bilirubin levels are within the normal range on laboratory tests.I do not have severe nerve damage in my hands or feet.My surgical tissue was checked for remaining cancer and used for further studies.Your alkaline phosphatase levels can be slightly higher than the normal range at the hospital.You have a white blood cell count of at least 1500 per cubic millimeter.Women who can have babies need to have a negative pregnancy test.My breast cancer is HER2-negative, and I've completed specific chemotherapy but still have significant cancer.
- Group 1: Group I (ixabepilone)
- Group 2: Group II (standard of care)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Ixabepilone been granted authorization from the FDA?
"This drug has been tested in clinical trials, which gives it a safety rating of 2. Though there is limited data on its efficacy, the testing conducted thus far indicates that Ixabepilone is relatively safe to use."
Does this research endeavor still have open enrollment for participants?
"At the moment, no further recruitment is occurring for this clinical trial which was initially posted on March 30th 2009. If you are searching for alternative studies to join, 4558 trials related to carcinoma and 5 research programmes involving ixabepilone currently have open slots."
What further investigations have been performed on Ixabepilone?
"Currently, there are 5 studies for Ixabepilone in progress with none of them being at the final phase. Although Baltimore is the primary hub for these trials, you can find research centres across 260 different locations that have undertaken this investigation."
What is the upper limit of participants in this clinical experiment?
"This clinical trial has concluded its search for participants. It was posted on March 30th 2009 and the last update occurred September 22nd 2022. If you are looking to join another medical study, currently there are 4558 trials accepting applicants with carcinoma diagnosis and 5 studies recruiting individuals taking Ixabepilone medication."
Share this study with friends
Copy Link
Messenger